Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Immunotherapy
KRAS
NSCLC
Overall survival
STK11
TTF
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
14
03
2022
accepted:
10
05
2022
pubmed:
28
6
2022
medline:
17
8
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small cell lung cancer (NSCLC). The primary objective is to evaluate, in a real-life setting, overall survival (OS) in patients with NSCLC according to the presence of STK11 mutation. The secondary objective is to assess time to treatment failure (TTF) for the first-line chemotherapy or immunotherapy. This observational multicentric study was conducted in Nouvelle-Aquitaine (France), for 24 months. Clinical, histopathological and imagery data were collected in each centre while the next-generation sequencing analysis was performed in Bordeaux Hospital University. Patient's data were longitudinally followed from NSCLC diagnosis date to the occurrence of censoring events (therapeutic failure or death, as applicable) or until the study end date. median OS from the first drug administration was significantly longer for STK11 The presence of STK11 mutation is associated with poor prognosis in NSCLC.
Sections du résumé
BACKGROUND
Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small cell lung cancer (NSCLC).
OBJECTIVE
The primary objective is to evaluate, in a real-life setting, overall survival (OS) in patients with NSCLC according to the presence of STK11 mutation. The secondary objective is to assess time to treatment failure (TTF) for the first-line chemotherapy or immunotherapy.
METHODS
This observational multicentric study was conducted in Nouvelle-Aquitaine (France), for 24 months. Clinical, histopathological and imagery data were collected in each centre while the next-generation sequencing analysis was performed in Bordeaux Hospital University. Patient's data were longitudinally followed from NSCLC diagnosis date to the occurrence of censoring events (therapeutic failure or death, as applicable) or until the study end date.
RESULTS
median OS from the first drug administration was significantly longer for STK11
CONCLUSION
The presence of STK11 mutation is associated with poor prognosis in NSCLC.
Identifiants
pubmed: 35759814
pii: S0959-8049(22)00305-7
doi: 10.1016/j.ejca.2022.05.026
pii:
doi:
Substances chimiques
Protein Serine-Threonine Kinases
EC 2.7.11.1
STK11 protein, human
EC 2.7.11.1
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-95Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PR, SA, CC, SGG, RV, AG, AC, LN, JPM, JB and POG have no conflicts of interest to disclose. CD has received consulting fees or honorarium from Astra-Zeneca, BMS, and accommodation and travelling expenses for meetings from Astra-Zeneca, BMS, PSD, Pfizer and Roche.